IZEA Worldwide GAAP EPS of -$0.03, revenue of $6.2M

IZEA Worldwide reported Q3 GAAP EPS of -$0.03 and revenue of $6.2M, down 23.5% year-over-year, according to the company.

Original reporting
Published Nov 12, 2026, 9:44 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 12, 2026, 9:47 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$IZEA
Bearish
medium confidence
Mentioned
$IZEA
Relevance
6/10
AlphAI data visualization · based on seekingalpha.com
Decision brief

The 30-second read

$IZEABearishLow
01

Why it matters

The earnings miss may trigger short‑term price declines, but longer‑term outlook depends on future growth initiatives.

02

Market read

Micro‑cap earnings release with negative surprise; limited broader market effect.

03

What to watch

Potential upcoming product launches or partnership announcements not covered in this brief.

Relevance 6/10Novelty 6/10Timing: after-hours

Background

IZEA Worldwide is a digital influencer marketing platform; the Q3 results were released via a press release on Seeking Alpha.

Company-level read

Ticker impact

$IZEABearishMedium confidence
Context

Q3 GAAP EPS of -$0.03 and revenue of $6.2M were disclosed, the first public release of these earnings figures.

Expected impact

likely downside as investors price in the earnings miss

Evidence & confidence

Micro‑cap earnings miss typically triggers short‑term sell pressure.

Market effects

Minimal impact on the broader digital marketing sector.

Limited to U.S. small‑cap investors.

Low

Counterpoint

Some investors may view the earnings miss as a buying opportunity if the company can pivot its business model.

Key entities

  • IZEA Worldwide, Inc.

    Digital influencer marketing platform reporting Q3 results.

Related articles

$IZEAMed

IZEA Reports Q3 2026 Revenue of $6.2 million, 94% increase in Managed Services Bookings

IZEA Worldwide, Inc. (IZEA) filed an SEC Form 8-K — Results of Operations and Financial Condition. IZEA Reports Q3 2026 Revenue of $6.2 million, 94% increase in Managed Services Bookings Enterprise Relationships Remain Strong Amid Market Uncertainties ORLANDO, Fla. ( November 12, 2026 ) - IZEA Worldwide, Inc. (NASDAQ: IZEA), a leading influencer marketing company that makes Cr

$IZEAMedAI 8/10

IZEA (IZEA) Q2 2026 Earnings Call Transcript

IZEA reported Q2 2026 revenue of $5.8M, down 36% YoY, and a net loss of $0.7M, as it shifts to larger enterprise accounts. Managed services bookings fell 19% YoY, while SaaS revenue declined 32%. The company has $46.6M in cash and no long-term debt. Management highlighted new enterprise wins and an active M&A pipeline, but noted macroeconomic uncertainty.

$IZEAMed

IZEA Reports Q2 2026 Revenue of $5.8 million, Advances Enterprise-Focused Growth Strategy

IZEA Worldwide, Inc. (IZEA) filed an SEC Form 8-K — Results of Operations and Financial Condition. IZEA Reports Q2 2026 Revenue of $5.8 million, Advances Enterprise-Focused Growth Strategy Enterprise Relationships Remain Strong Amid Market Uncertainties ORLANDO, Fla. ( August 11, 2026 ) - IZEA Worldwide, Inc. (NASDAQ: IZEA), a leading influencer marketing company that makes Cr

$NOKMed

LightCounting:: November 2026 Nokia SReXperts

Nokia hosted its SReXperts/Wavelengths conference in November 2026, focusing on AI's impact on connectivity and its solutions for customers. The company reported strong Q3 2026 earnings, with AI & Cloud sales doubling year-over-year and $1.7 billion in new orders. Nokia expects 25-30% growth in its Optical and IP Networks businesses in 2027. The company aims to help telecom operators adapt to AI-driven changes and capitalize on new opportunities.

$IBRXLow

IBRX Stock Eyes Best Year Ever: Founder Teases 12 Months Of ‘Stealth’ NantWorks Reveals — Cancer Tech, AI Chips And Satellites

ImmunityBio (IBRX) reported a 53% increase in Q3 net product revenue to $48.7M, with 92% growth for the first nine months. The company is testing its drug Anktiva for sepsis and aims to expand FDA approval for bladder cancer. NantWorks, led by Patrick Soon-Shiong, plans a blockchain-based exchange for tokenized securities. IBRX stock has risen 195% over the past year, with bullish retail sentiment on Stocktwits.